Skip Navigation

Cost-effective screening and treatment of Hepatitis C

Series Title(s):
Issue brief (Leonard Davis Institute of Health Economics)
Author(s):
Weiner, Janet, author
Linas, Benjamin, author
Contributor(s):
Leonard Davis Institute of Health Economics, issuing body.
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, issuing body.
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, September 2018
Language(s):
English
Format:
Text
Subject(s):
Cost-Benefit Analysis
Hepatitis C -- diagnosis
Mass Screening -- economics
Eligibility Determination
Health Policy
Hepatitis C -- drug therapy
Insurance Coverage -- economics
Mass Screening -- trends
Medicaid -- economics
Sofosbuvir -- economics
Sofosbuvir -- therapeutic use
Practice Guidelines as Topic
Humans
United States
Centers for Disease Control and Prevention (U.S.)
Genre(s):
Technical Report
Abstract:
In just five years, hepatitis C has changed from a difficult-to-treat chronic condition to one that is readily cured by a short course of medication. Medical breakthroughs have now created the possibility of eliminating the transmission of HCV, but also bring a new challenge for the health system--how to identify individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving treatments. This Issue Brief reviews recent evidence on the cost-effectiveness of screening and treatment strategies, and makes the case for universal, one-time HCV screening for all US adults.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (7 pages))
Illustrations:
Illustrations
NLM Unique ID:
101735705 (See catalog record)
Series Title(s):
Issue brief (Leonard Davis Institute of Health Economics)
Author(s):
Weiner, Janet, author
Linas, Benjamin, author
Contributor(s):
Leonard Davis Institute of Health Economics, issuing body.
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, issuing body.
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, September 2018
Language(s):
English
Format:
Text
Subject(s):
Cost-Benefit Analysis
Hepatitis C -- diagnosis
Mass Screening -- economics
Eligibility Determination
Health Policy
Hepatitis C -- drug therapy
Insurance Coverage -- economics
Mass Screening -- trends
Medicaid -- economics
Sofosbuvir -- economics
Sofosbuvir -- therapeutic use
Practice Guidelines as Topic
Humans
United States
Centers for Disease Control and Prevention (U.S.)
Genre(s):
Technical Report
Abstract:
In just five years, hepatitis C has changed from a difficult-to-treat chronic condition to one that is readily cured by a short course of medication. Medical breakthroughs have now created the possibility of eliminating the transmission of HCV, but also bring a new challenge for the health system--how to identify individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving treatments. This Issue Brief reviews recent evidence on the cost-effectiveness of screening and treatment strategies, and makes the case for universal, one-time HCV screening for all US adults.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (7 pages))
Illustrations:
Illustrations
NLM Unique ID:
101735705 (See catalog record)